RESEARCH ARTICLE

Retrovirus-Mediated Expression of E2A-PBX1 Blocks Lymphoid Fate but Permits Retention of Myeloid Potential in Early Hematopoietic Progenitors

Mark W. Woodcroft¹, Kyster Nanan¹, Patrick Thompson¹, Kathrin Tyryshkin¹, Steven P. Smith², Robert K. Slany³, David P. LeBrun¹ *

1 Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada, 2 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada, 3 Department of Genetics, University Erlangen, Erlangen, Germany

* DPL1@queensu.ca

Abstract

The oncogenic transcription factor E2A-PBX1 is expressed consequent to chromosomal translocation 1;19 and is an important oncogenic driver in cases of pre-B-cell acute lymphoblastic leukemia (ALL). Elucidating the mechanism by which E2A-PBX1 induces lymphoid leukemia would be expedited by the availability of a tractable experimental model in which enforced expression of E2A-PBX1 in hematopoietic progenitors induces pre-B-cell ALL. However, hematopoietic reconstitution of irradiated mice with bone marrow infected with E2A-PBX1-expressing retroviruses consistently gives rise to myeloid, not lymphoid, leukemia. Here, we elucidate the hematopoietic consequences of forced E2A-PBX1 expression in primary murine hematopoietic progenitors. We show that introducing E2A-PBX1 into multipotent progenitors permits the retention of myeloid potential but imposes a dense barrier to lymphoid development prior to the common lymphoid progenitor stage, thus helping to explain the eventual development of myeloid, and not lymphoid, leukemia in transplanted mice. Our findings also indicate that E2A-PBX1 enforces the aberrant, persistent expression of some genes that would normally have been down-regulated in the subsequent course of hematopoietic maturation. We show that enforced expression of one such gene, Hoxa9, a proto-oncogene associated with myeloid leukemia, partially reproduces the phenotype produced by E2A-PBX1 itself. Existing evidence suggests that the 1;19 translocation event takes place in committed B-lymphoid progenitors. However, we find that retrovirus-enforced expression of E2A-PBX1 in committed pro-B-cells results in cell cycle arrest and apoptosis. Our findings indicate that the neoplastic phenotype induced by E2A-PBX1 is determined by the developmental stage of the cell into which the oncoprotein is introduced.
Introduction

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Approximately 5% of ALL cases are associated with a reciprocal translocation between chromosome bands 1q23 and 19p13.3 [1]. In the vast majority of cases, this leads to the fusion of the E2A (also called TCF3) and PBX1 genes, resulting at the protein level in fusion of the N-terminal two thirds of E2A with most of PBX1 to create the oncogenic transcription factor E2A-PBX1. Relative to other B-progenitor ALL subtypes, leukemic blasts with t(1;19) typically manifest a more mature immunophenotype characterized by expression of cytoplasmic μ heavy chain thus justifying the term "pre-B-cell ALL" to denote such cases [1;2].

Although t(1;19) is associated almost exclusively with pre-B-cell ALL, B-lymphoid disease is generally not replicated in murine models of E2A-PBX1 oncogenesis. In the initial transgenic mouse model, E2A-PBX1 expression directed by the Eμ enhancer resulted in T-progenitor lymphoma after a brief latency period [3]. More recently, Bijl et al. were successful in forcing the development of B-progenitor ALL by crossing CD3ε−/− mice, which fail to develop mature T-cells, with transgenic mice expressing E2A-PBX1 under the control of lymphoid specific promoter/enhancer elements [4]. Some of these progeny developed leukemia that manifested B-lymphoid immunophenotypic features and immunoglobulin gene rearrangements after a long latency period, although in half of the cases a combined lymphoid/myeloid phenotype was evident. Therefore, these transgenic approaches have not addressed the need for an experimentally tractable model of E2A-PBX1-driven pre-B-cell leukemia in order to elucidate mechanistic aspects of E2A-PBX1-mediated oncogenesis in the context of B-lymphopoiesis.

Adoptive transfer of bone marrow cells that have been transduced ex vivo with an E2A-PBX1-expressing retroviral vector generally leads to an aggressive myeloproliferative neoplasm, although instances of T-progenitor ALL have also been observed [5;6]. These transplantation studies have not adequately delineated the impact of E2A-PBX1 on lymphopoiesis, in part because the phenotypic analyses performed on engrafted, E2A-PBX1-expressing cells were carried out after the recipient animals began to show signs of illness, when the bone marrow was densely packed with immature myeloid progenitors rendering it difficult to assess the effect of E2A-PBX1 on non-myeloid lineages. Furthermore, these experiments were carried out using retroviral vectors that did not allow transduced cells and their progeny to be distinguished on a cell-by-cell basis by flow cytometry.

Therefore, the need persists to investigate the hematopoietic impact of E2A-PBX1 on the fate of early progenitors in order to elucidate E2A-PBX1 function and inform the eventual development of an experimentally tractable model of E2A-PBX1-induced B-lymphoid ALL. In the present study, we establish stable, retrovirus-mediated expression of E2A-PBX1 in uncommitted hematopoietic progenitors or committed B-lymphoid progenitors and determine the hematopoietic and transcriptional consequences in vivo and in vitro.

Materials and Methods

Mice

BALB/c mice 8–12 weeks old were purchased from Charles River and housed in the Queen’s University Animal Care Facility. These animals were handled according to a protocol (LeBrun-2009-021) specifically approved for this study by the Queen’s University Animal Care Committee. After transplantation, recipient mice were maintained on acidified water in micro-isolator units under sterile conditions.
Cell lines and culture conditions

The cell lines 293T (ATCC CRL-3216) and NIH 3T3 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories Inc., Etobicoke, ON), 1× antibiotic/antimycotic solution (Gibco, Carlsbad, CA), and 2 mM L-glutamine. The OP9 cell line [7], a gift from Dr. Juan Carlos Zúñiga-Pflücker, Sunnybrook Health Sciences Centre, Toronto, Ontario, was cultured in Iscoves Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS (HyClone, Logan, UT), 1× antibiotic/antimycotic solution, 10 μM β-mercaptoethanol and 2 mM L-glutamine. OP9 cells were subjected to 15 Gy of γ radiation from a 137Cs source prior to co-culture with fetal liver-derived hematopoietic progenitor cells.

Plasmids and generation of retroviral supernatants

The MIEV-EP1b and MIEV-EP1b-L20A retroviral backbone plasmids were constructed by excising the complementary DNA for E2A-PBX1 or its L20A mutant, respectively, from pBlue-Script-SK(-) with the restriction enzymes NotI and SalI and ligating them into a MIEV retroviral backbone plasmid that had been prepared by digestion with the same enzymes [5]. For construction of MIEV-EP1b-N51S, the mutation-containing portion of E2A-PBX1 was excised from pGD-EP1b-N51S (a gift from Dr. Mark Kamps) with BspMI and Ncol and ligated into the MIEV-EP1b vector that had been digested with the same enzymes. All constructs were verified by DNA sequencing. Retroviral supernatants were generated by co-transfecting 293T cells with 7.5 μg of MIEV-based backbone plasmid and 7.5 μg MCV-ecopac retroviral packaging plasmid using standard calcium phosphate methodology. Supernatants were stored at -80°C.

Retroviral transduction and bone marrow transplantation assays

Bone marrow was harvested from the femurs and tibias of 8 to 10 week-old female BALB/c mice. Lineage-depleted (lin−) cells were obtained using a lineage depletion kit (Miltenyi Biotec Inc., Auburn, CA) according to the manufacturer’s instructions. Following depletion, the cells were resuspended in pre-stimulation mix (IMDM containing 15% fetal bovine serum, 2 mM L-Glutamine, 1× antibiotic/antimycotic solution, 50 μg/mL gentamicin (Sigma Aldrich, Oakville, ON), 10 ng/mL interleukin-3 (IL-3), 10 ng/mL IL-6 and 50 ng/mL murine stem cell factor (SCF)); all recombinant cytokines were purchased from Peprotech. Twenty-four hours after the initial pre-stimulation period, 2.0 × 10⁶ cells were pelleted and resuspended in 2.7 mL of retroviral supernatant, 0.3 mL of IMDM containing 100 ng/mL IL-3, 100 ng/mL IL-6, 500 ng/mL SCF and 50 μg/mL polybrene was added and the cell suspensions were transferred to 6-well dishes. Cells were transduced by spinoculation at 1800g for 2 h at 25°C. Following the spin, retroviral supernatant was removed and replaced with fresh pre-stimulation mix. The next day, cells were subjected to a second round of transduction and then 4.0 × 10⁵ transduced cells were mixed with 2.0×10⁶ whole bone marrow cells in Hank’s balanced salt solution (HBSS) and injected into the tail vein of lethally irradiated (9 Gy) BALB/c recipient animals. Mice were sacrificed by cervical dislocation three weeks post-transplantation prior to displaying signs of morbidity. More generally, mice were handled according to protocol LeBrun-2013-022-Or approved by the University Animal Care Committee of Queen’s University.

Isolation, transduction and culture of primary hematopoietic progenitor cells

Fetal livers were isolated from E12.5–14.5 BALB/c embryos and homogenized in phosphate-buffered saline (PBS) containing 1 mM EDTA. Lin− fetal liver progenitor (FLP) cells were
purified as described above, re-suspended in retroviral supernatant containing 5 μg/mL poly-
brene and plated in a 6-well plate containing 7.0 × 10^4 irradiated OP9 cells. The plates were
spun for 2 h at 1800g at 25°C and then the retroviral supernatant was aspirated and replaced
with 3 mL of OP9 media supplemented with 20 ng/mL of recombinant interleukin-7 (IL-7) or
a 1:100 dilution of J558-IL-7-conditioned supernatant. For some experiments, cultures were
additionally supplemented with 20 ng/mL SCF. Cells were transferred to fresh, irradiated OP9
feeder cells every 3–4 days in a manner that accorded with published guidelines for maintain-
ing optimal OP9 cell density [8]. In order to establish expression of estrogen-regulatable
E2A-PBX1 in B-lymphoid progenitors, "pre-B-1" cells were flow sorted from the bone marrow
of adult mice and expanded ex vivo in the presence of IL-7 and OP9 cells, according to a pub-
lished protocol [8]. These cells were then transduced with p210^{BCR-ABL} by co-culture with
293T packaging cells that had been transiently transfected with the retroviral backbone plasmid
MIEV puro BCR-ABL (a gift from Dr. Peter Greer, Queen's University) and MCV-ecopac plas-
mids and then selected in 1 μg/mL puromycin. After confirmation of IL-7- and OP9-indepen-
dent growth and a B-lymphoid (CD19+, CD11b-) immunophenotype, these cells were infected
by spinoculation with MSCVneo-EPΔ623ER, a gift of Dr. Mark Kamps, University of Califor-
nia San Diego, selected in 1 mg/mL G418 and cloned by limiting dilution in 96-well plates.
Expression of EPΔ623ER in the clone designated 3PER12 was confirmed by immunoblotting.

Flow cytometry
For immunophenotyping, cells were washed in PBS and re-suspended in PEB (PBS containing
2 mM EDTA and 0.5% bovine serum albumin (BSA)) at 1.0 × 10^7 cells/mL. Anti-CD16/32 was
added to block non-specific antibody binding to Fc receptors and then cells were incubated for
5 minutes on ice. Subsequently, 1.0 × 10^6 cells were incubated on ice for 20 minutes in 100 μL
of PEB containing antibodies to the surface markers of interest; antibody details are provided
in S1 Table. Cells were washed twice with ice-cold PBS and re-suspended in 500 μL of PBS
prior to analysis. Apoptosis assays were performed using the Annexin-V-PE apoptosis kit
according to the manufacturer's instructions (EMD Millipore, Darmstadt, DE). Cell cycle anal-
yses were performed using DyeCycle Green according to the manufacturer's instructions (Life
Technologies, Carlsbad, CA). Flow cytometry was performed using a FC500 cytometer (Beck-
man Coulter, Mississauga, ON). All data analysis was carried out using the FlowJo software
platform (Treestar Inc., Ashland, OR).

RNA extraction and quantitative RT-PCR
Total RNA was extracted using the RNeasy Midi kit according to the manufacturer's instruc-
tions (Qiagen, Valencia, CA) and 50 μg was used for each reaction. Quantitative reverse tran-
scriptase polymerase chain reaction (qRT-PCR) for Bmi1 was carried out on an Mastercycler ep realplex4
instrument (Eppendorf Inc., Hauppauge, NY) using the TaqMan RNA-to-Ct One
Step kit according to the manufacturer's instructions (Applied Biosystems, Carlsbad, CA) with
the following TaqMan gene expression assays: Bmi1 (Mm003053308_g1) and B2m
(Mm00437762_m1). qRT-PCR for other transcripts made use of the Biorad iScript One-step
RT-PCR kit and the following TaqMan assays: Msix1 (Mm00487664_m1), Mycn
(Mm00476449_m1), Gata3 (Mm00484683_m1), Myc (Mm00487804_m1), Rora
(Mm01173766_m1), Il6 (Mm00446190_m1), Kit (Mm00445212_m1), Pax5
(Mm00435501_m1), Ebf1 (Mm00432948_m1), B2m (Mm00437762_m1) and Tbp
(Mm00446971_m1). Relative transcript abundance was calculated using the standard ΔΔCT
method; B2m was used as the reference for Bmi1 quantification and Tbp was used for the other
transcripts. P-values shown or referred to in the figures were calculated using an unpaired, two-tailed Student’s t-test.

Immunoblotting

Immunoblotting was carried out as previously described using anti-E2A (sc-416; Santa Cruz Biotechnology, Santa Cruz, CA), anti-Ebf1 (Epitomics, Burlingame, CA; catalog number 3197–1), anti-Pax5 (Santa Cruz; catalog number sc-1974), anti-Bmi1 (EMD Millipore, Billerica, MA; catalog number 05–637) [9]. Anti-enhanced green fluorescent protein (GFP) (Roche, Laval, QC; catalog number 11814460001) or anti-γ-tubulin (Sigma; catalog number T5326) were used as loading controls.

Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) followed by quantitative PCR (ChIP-qPCR) was carried out using 2×10⁶ cell equivalents of chromatin per immunoprecipitation (IP) according to a published protocol [10]. Immunoprecipitations were carried out using 2 μg of anti-H3K4me3 (EMD Millipore; catalog number 07–473) or anti-H3K27me3 (EMD Millipore; catalog number 07–449). Quantitative PCR was carried out using SYBR Green chemistry with primers (Ebf1-1, -2 and -3, and Pax5-2 and -3) that amplify regions within the Ebf1 or Pax5 promoters demonstrated previously to be differentially associated in B-lymphoid progenitors with the H3K27me3 versus H3K4me3 chromatin marks [11].

Limiting dilution analysis

Serial dilutions corresponding to 1.5, 3, 6, 12, 24, and 48 cells per 100 μL were prepared in medium supplemented with IL-7 and SCF supernatants. For each dilution, 100 μl was plated in each of 16 wells of a 96-well plate; each well also contained 7.0 × 10³ irradiated OP9 cells. After 7 days, wells containing at least 50 viable cells were considered as indicating culture initiation and enumerated by microscopy. Data were analyzed using the extreme limiting dilution analysis (ELDA) tool [12]. Statistical significance was assessed using the χ² test.

Gene expression microarray analysis

E2A-PBX1-transduced FLPs and empty vector-transduced, FLP-derived, CD19+ pro-B-cells were maintained for approximately 40 days in the presence of IL-7 and SCF prior to purification of total RNA; the pro-B-cells were co-cultured with OP9 stromal cells. Total RNA was extracted as described above and quality was assessed using an Agilent Bioanalyzer (Agilent Technologies Canada Inc., Mississauga, ON). For each sample, 300 ng of RNA was used as a template for amplification and Cy3 labeling using the Agilent QuickAmp kit; labeling and amplification efficiency were assessed using a Nanodrop spectrophotometer. For each sample, 1.65 μg of labeled copy RNA was hybridized to a mouse whole genome 4 × 44 K gene expression array (Agilent). After 17 hours of hybridization, arrays were washed and scanned using an Agilent Microarray Scanner. Feature extraction software (10.5.1.1) was used to extract expression data from array images and to perform initial data preprocessing, including background correction. The data were then further preprocessed using the Agi4x44PreProcess Bioconductor package [13]. The original package was modified to apply LOESS normalization between arrays [14]. Subsequent data analysis was carried out using MATLAB (Mathwork, Inc., Massachusetts, USA). Probes that were identified as extreme outliers on the fold-change between replicate samples were removed from further analysis. The criterion for outlier detection was based on the inter-quantile range (IQR) method with α = 3 [15;16]. Finally, probes with low
absolute expression levels were filtered out. The comparison of the remaining 23,457 probes for 8 cell samples is described further in the Results section.

Results

Enforced expression of E2A-PBX1 in vivo impairs differentiation in multiple hematopoietic lineages

In order to elucidate the impact of E2A-PBX1 on normal hematopoiesis, lethally-irradiated mice were transplanted with lin\(^-\) bone marrow cells that had been transduced with either control or E2A-PBX1-expressing retroviruses that co-express GFP. These animals were sacrificed three weeks after transplantation, before the emergence of any signs of illness, and cells from the bone marrow, spleen and thymus were isolated and analyzed.

E2A-PBX1-transduced cells failed to differentiate into committed CD45R\(^+\)/CD19\(^+\) B-lymphoid progenitors; results from the bone marrow and spleen of a representative animal are shown in Fig 1A and 1B, respectively. No cells expressing surface IgM were observed among the GFP\(^+\) fraction in either tissue (data not shown). This was in contrast to control cells infected with the empty MIEV retroviral vector, in which CD45R\(^+\)/CD19\(^+\) progenitors constituted 18% of cells in the bone marrow and fully 44% of cells in the spleen. A marked reduction in the number of CD49b\(^+\) cells in the spleen suggested impaired natural killer cell production.

The thymus contained a reduced number of GFP\(^+\) cells expressing E2A-PBX1 relative to controls, consistent with impaired seeding of this organ due to impaired initiation of T-lymphopoiesis by E2A-PBX1-expressing progenitors (Fig 1C). Furthermore, co-staining for CD4 and CD8 showed a marked impairment in the ability of E2A-PBX1-expressing cells to mature beyond the double-negative stage. Equivalent results were observed in 4 animals transplanted with E2A-PBX1-transduced cells. Therefore, retrovirus-enforced expression of E2A-PBX1 in lin\(^-\) bone marrow-derived hematopoietic progenitors markedly impairs lymphoid development and, in particular, imposes an almost absolute block to B-lymphopoiesis.

Beyond the lymphoid compartment, there was impairment in maturation from CD11b\(^-\)/Gr1\(^-\) to CD11b\(^+\)/Gr1\(^+\) cells in the bone marrow and a reduction in F4/80\(^+\) macrophages in the spleen, suggesting a relative impairment of granulocytic/monocytic differentiation (Fig 1A and 1B). A modest reduction in Ter-119\(^+\) progenitors in the bone marrow suggested impaired erythroid differentiation (Fig 1A). Notwithstanding the evidence of impaired differentiation in multiple lineages, E2A-PBX1-expressing cells engrafted rapidly and accumulated in the bone marrow and spleen as an expanded population of CD11b\(^+\) cells. Therefore, enforced expression of E2A-PBX1 in this bone marrow transplantation model permits retention of granulocyte/monocyte lineage potential, albeit with a relative impairment of maturation.

E2A-PBX1 antagonizes B-lymphoid differentiation in vitro through a mechanism that requires binding to both DNA and transcriptional co-activators

In order to determine hematopoietic lineage fate, lineage-specific inductive signals must act upon multipotent progenitors that are competent to respond to them [17]. Therefore, the competency of E2A-PBX1-expressing, lineage-uncommitted progenitors to respond to environmental signals that normally induce B-lymphoid differentiation was investigated using an established, more experimentally tractable in vitro system. Lin\(^-\) hematopoietic progenitors harvested from day 12 to 14 fetal livers differentiate to committed pro-B-cells (also called “pre-B1 cells”) after 9 to 14 days of co-culture with OP9 stromal cells in the presence of IL-7 and SCF [18]. Whereas the immunophenotype of control cells confirmed their CD45R\(^-\)/CD19\(^-\),
Fig 1. E2A-PBX1-expressing bone marrow cells reconstitute early myeloid but not B-lymphoid development in transplanted mice. Primary murine bone marrow cells were transduced with E2A-PBX1-expressing or control retroviral vectors and injected into the tail vein of lethally-irradiated, syngeneic recipient mice. Mice were sacrificed 3 weeks later. Immunophenotypic analysis of (A) bone marrow, (B) spleen, and (C) thymus are shown from representative animals. Events were gated so as to restrict all of these analyses to the GFP+ cell population.

doi:10.1371/journal.pone.0130495.g001
B-lymphoid-committed, status (Fig 2A), most E2A-PBX1-transduced cells displayed a relatively immature, lineage-ambiguous phenotype characterized by the absence of CD45R or CD19, persistent expression of abundant CD117 and Sca-1, and variable expression of IL-7R and CD11b. Initially, minor populations of CD45R+/CD19+ (24%) and CD45R+/CD19- (11%) cells were observed. While the CD45R+/CD19+ population was lost with continued culture (compare the CD45R/CD19 plots at 14 and 25 days), the CD45R+/CD19- population was retained. The presence of these cells could reflect slight leakiness of the differentiation block or the presence at the time of retroviral transduction of a small number of lin- progenitors with a bias towards the B-lymphoid fate. Equivalent results were obtained in two experiments. Despite its obvious effect on hematopoietic differentiation, expression of E2A-PBX1 did not affect growth kinetics during the first 14 days after retroviral transduction (S1 Fig). However, the ability of GFP+, E2A-PBX1-transduced cells to out-compete GFP- cells by 25 days after transduction (Fig 2A) suggests the outgrowth of more proliferative subpopulations of cells many of which express E2A-PBX1 more abundantly. This is further supported by the right-ward shift in GFP signal intensity observed by day 25 for E2A-PBX1-transduced cells (Fig 2A). However, given the persistent expression of CD117 in E2A-PBX1-transduced FLPs, we considered whether the immature, E2A-PBX1-transduced cells were dependent on SCF, the ligand for CD117. Lin- FLPs were deprived of SCF 5 days after transduction and the cumulative number of GFP+ cells was determined 9 days later. E2A-PBX1-transduced FLPs suffered a greater impairment of proliferation upon SCF deprivation than did control cells, indicating greater dependency on this cytokine (Fig 2B). Limiting dilution in 96-well plates and the web-based ELDA tool were used to determine the prevalence of culture-initiating cells. Whereas culture-initiating cells were present at a frequency of 1/12.6 cells among vector-infected FLPs, the frequency among E2A-PBX1-infected FLPs was nine-fold higher, at 1/1.4 (95% CI 1/17.5-1/9.06 versus 1/2.13-1/0.954, respectively, p < 0.001; Fig 2C) [12]. Equivalent results were obtained in three replicate experiments. The presence of features characteristic of early hematopoietic progenitors, including an immature immunophenotype, persistent differential responsiveness to SCF and a higher prevalence of culture-initiating cells in FLPs forced to express E2A-PBX1, supports the idea that E2A-PBX1 antagonizes aspects of hematopoietic maturation and enforces persistence of features characteristic of hematopoietic stem cells (HSCs) or early progenitors.

E2A-PBX1 induces proliferation in fibroblasts in culture or T-progenitor lymphoma in transgenic mice through a mechanism that does not require DNA binding mediated by the PBX1 homeodomain [3;19]. B-lymphoid commitment in the FLP model requires the E2a gene products [20]. These considerations raise the possibility that blocked B-lymphoid differentiation in our system could be attributable to dominant-negative effects on wild-type E2a gene products, perhaps involving squelching through sequestration of transcriptional co-activators by E2A-PBX1. The L20A amino acid substitution within activation domain 1 (AD1) of E2A-PBX1 markedly impairs binding to the transcriptional co-activator and histone acetyltransferase CBP/p300 whereas the N51S substitution in the PBX1 homeodomain disrupts DNA binding [5;21]. Either of these substitutions completely abrogated the differentiation blockade imposed by E2A-PBX1 in the FLP-based B-lymphopoiesis model (Fig 3A). The loss of the differentiation block was not due to sub-threshold transgene expression as both the L20A and N51S mutants are expressed at levels comparable to un-modified E2A-PBX1 (Fig 3B). These results, which were obtained in at least two independent experiments, support a model in which E2A-PBX1 blocks B-lymphoid differentiation through a mechanism that requires the recruitment of CBP/p300 to genomic loci bound by the PBX1 homeodomain.

We recently used NMR spectroscopy to demonstrate binding of activation domain 2 (AD2) of E2A to the KIX domain of CBP and determined that an A400L substitution within AD2 increases the affinity of this interaction by more than two-fold (dissociation constant (Kd)
changes from 17 to 7.2 μM) [22]. Addition of the A400L substitution to full-length, L20A-substituted E2A-PBX1 so as to create an L20A/A400L double-mutant partially reconstituted the differentiation block that was lost as a result of the L20A substitution alone (Fig 3A) such that cells emitting brighter GFP fluorescence, and therefore presumably expressing more E2A-PBX1 L20A/A400L, failed to penetrate into the B-lymphoid compartment while cells with
dimmer GFP fluorescence succeeded in achieving B-lymphoid commitment. This effect is attributable to the A400L substitution as the L20A/A400L double-mutant is expressed at levels equivalent to wild type E2A-PBX1 and the L20A single mutant [22]. These results suggest that AD2 can supplant defective AD1 in recruiting CBP/p300 to DNA-bound E2A-PBX1 and that this is marginally sufficient for blocking differentiation. More generally, these results provide additional support for the importance of CBP/p300 recruitment in mediating the differentiation blockade imposed by E2A-PBX1.
E2A-PBX1-transduced FLPs can undergo myeloid differentiation in response to GM-CSF

Although the vast majority of E2A-PBX1-expressing FLPs cultured with IL-7 and SCF remain relatively undifferentiated (Fig 2A), bone marrow progenitors overwhelmingly adopt a CD11b+ myeloid immunophenotype after transplantation (Fig 1A and 1B), suggesting that E2A--PBX1-expressing progenitors remain responsive to pro-myeloid stimuli provided in the bone marrow or splenic microenvironments. This possibility was investigated using the FLP model by transplanting cultured E2A-PBX1-transduced FLPs into lethally-irradiated recipient mice. These rapidly developed leukemia; all three animals succumbed to the disease by 38 days post-transplantation. One mouse was euthanized at 21 days post-transplantation, prior to manifesting signs of illness. Immunophenotypic analysis of bone marrow (Fig 4A) and spleen (Fig 4B) from this animal revealed that the vast majority of GFP+ cells were CD11b+, indicating myeloid differentiation. This observation was replicated in vitro; 14 days after transduction, E2A--PBX1-expressing FLPs were transferred from media containing IL-7 and SCF to media in which the only exogenously added recombinant cytokine was murine granulocyte/macrophage colony stimulating factor (GM-CSF). Compared to E2A-PBX1-expressing FLPs cultured in the presence of IL-7 and SCF, most of which were CD11b+, CD117+ (Fig 2A), the vast majority of cells cultured in GM-CSF acquired a myeloid immunophenotype reminiscent of that of the GFP+ cells.
that accumulated in the bone marrow of transplanted mice: CD11b+, Gr-1−, CD117+/-, CD45R−, CD19− and IL-7R− (Fig 4C and data not shown). Equivalent results were obtained in two independent experiments. Therefore, the results obtained using our FLP-based model agreed with those based on transplantation of bone marrow progenitors in showing that uncommitted progenitors that express E2A-PBX1 become leukemogenic and manifest a dense block to B-lymphoid commitment while remaining amenable to the induction of granulocytic/monocytic differentiation.

E2A-PBX1 blocks B-lymphopoiesis prior to the common lymphoid progenitor stage

During B-lymphopoiesis, the progeny of HSCs undergo progressive restriction of their lineage potential through the multipotent progenitor (MPP), lymphoid-primed MPP and common lymphoid progenitor (CLP) stages [23]. Commitment to the B-lineage occurs subsequently at the pro-B-cells stage, which coincides with surface expression of CD19. The B-lymphopoietic transcription factor genes Ebf1 and Pax5 are subjected to Polycomb group- (PcG) mediated silencing in HSCs and MPPs but are transcriptionally induced when cells reach the CLP stage [11]. Accordingly, the Ebf1 and Pax5 promoters are associated with the PcG-mediated repressive mark H3K27me3 in early hematopoietic and non-lymphoid progenitors, whereas they acquire the activating H3K4me3 mark in CLPs. Evaluating the E2A-PBX1-expressing FLPs indicated low to absent expression of Ebf1 or Pax5 at either the protein or transcript levels (Fig 5A and 5C). Examining the chromatin status at the Ebf1 and Pax5 promoters by ChIP-qPCR demonstrated failure of either promoter to switch from the silenced H3K27me3- to the active H3K4me3-marked state in E2A-PBX1-expressing FLPs (Fig 5B and 5D). Therefore, B-lymphopoiesis is blocked prior to the CLP stage as a consequence of E2A-PBX1 expression.

Forced expression of E2A-PBX1 deregulates hematopoietic genes

Gene expression microarray analysis was used to further elucidate the effects of E2A-PBX1 on hematopoiesis. RNA from biological replicates of E2A-PBX1-transduced FLPs and vector-transduced, FLP-derived, CD19+ pro-B-cells was evaluated for differential gene expression. The immunophenotype of the E2A-PBX1-tranduced cells used for gene expression analysis was equivalent to that shown in Fig 2A for day 25. RNA prepared from primary, uncultured lin- FLPs and primary CD11b+ myeloid bone marrow cells was evaluated for comparison with the cultured cells. Hierarchical cluster analysis based on gene expression profiles of all of the probes that remained after initial data filtering (n = 23,457) showed that the FLP-derived pro-B-cells and the FLP-derived E2A-PBX1-expressing cells clustered together (Fig 6A). This is consistent with the common origin of these cell types from lin- FLPs and with their history of having been maintained in tissue culture for several passages. Further analysis of the data identified 3,203 probes representing 2,235 genes that showed at least a four-fold difference in expression between E2A-PBX1-expressing cells and FLP-derived pro-B-cells; these are listed in S2 Table. In S3 Table, these genes are organized according to their expression in lin- or myeloid cells. For example, abundant expression of Mycn, Il6, Bcl2, Flt3 and Hoxa9 was exclusive to E2A-PBX1-expressing FLPs, whereas abundant Rora, Meis1, Gata 2 and Gata3 was observed in both E2A-PBX1-expressing and lin- FLPs. Differential up-regulation of Rora, Meis1, Myc, Mycn, Gata3, Il6 and Kit in E2A-PBX1-expressing relative to FLP-derived pro-B-cells was confirmed by qRT-PCR (Fig 6B). Enrichment analysis for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) [24]. The top 20 KEGG pathways over-represented by genes up- or down-regulated downstream of E2A-PBX1 are listed in Tables 1 and 2, respectively; the full lists of pathways and the probe ID numbers of the genes associated with each
Genes up-regulated in E2A-PBX1-expressing cells and over-represented from the "Cytokine-cytokine receptor interaction" pathway included many genes encoding cytokines or cytokine receptors, such as Csf1r, Flt1, Flt3, Met, Hgf, Pdgfc, Vegfc, while genes over-represented from the "Hematopoietic cell lineage" pathway included genes characteristically expressed in myeloid cells and progenitors, such as Cd14, Cd33, Cd36, Gp1ba and Gp1bb. Genes down-regulated in E2A-PBX1-expressing cells and over-represented from the "Pathways in cancer" pathway included known tumor suppressor genes, such as Cdkn1b, Pten and Foxo1; genes over-represented from the "B cell receptor signaling pathway" included those encoding signaling molecules and transcription factors such as Cd19, Cd79a, Cd79b, Blnk, Nfkb1a and Tcf3. These patterns of gene expression are consistent with failure of

Fig 5. B-lymphopoiesis is blocked at a point prior to the CLP stage in FLPs expressing E2A-PBX1. (A) Immunoblotting indicates markedly reduced or absent expression of the B-lymphopoietic transcription factors Ebf1 and Pax5 in FLPs expressing E2A-PBX1 relative to those infected with the empty retroviral vector. The apparent weak signal for Pax5 in the E2A-PBX1 lane may represent spillover between lanes. Anti-γ-tubulin serves as a loading control. (B) ChIP-qPCR results obtained from chromatin prepared from control, vector-infected FLPs indicate prevalence of the activating H3K4me3 mark relative to the silencing H3K27me3 mark at the Ebf1 and Pax5 promoters. Error bars represent 95% confidence limits. (C) Results from qRT-PCR indicating marked reduction or absence of the Ebf1 and Pax5 transcripts in FLPs expressing E2A-PBX1 relative to control cells. The asterisk indicates failure to observe a PCR product in either of the 2 independent samples. Error bars indicate one standard deviation. (D) ChIP-qPCR results obtained from chromatin prepared from FLPs expressing E2A-PBX1 indicate prevalence of the silencing H3K27me3 mark relative to the activating H3K4me3 mark at the Ebf1 and Pax5 promoters.

doi:10.1371/journal.pone.0130495.g005

pathway are provided in S4 and S5 Tables.
Fig 6. Forced expression of E2A-PBX in FLPs deregulates hematopoietic genes. (A) Hierarchical cluster analysis performed on expression data from gene expression microarrays indicates that the closest relationship to E2A-PBX1-expressing FLPs is with pro-B-cells that were differentiated from FLPs in vitro. (B) Confirmation by qRT-PCR of differential expression of genes identified initially using expression microarrays in E2A-PBX-expressing versus pro-B-cells derived from vector-infected FLPs. Data are from 2 independent samples. Error bars indicate one standard deviation; p-values are less than 0.005 for each comparison.

doi:10.1371/journal.pone.0130495.g006
Table 1. KEGG pathways overrepresented by genes up-regulated downstream of E2A-PBX1.

| KEGG pathway term                              | Number of genes | \(P\) value  |
|------------------------------------------------|-----------------|--------------|
| Cytokine-cytokine receptor interaction         | 76              | 4.34E-13     |
| Hematopoietic cell lineage                     | 33              | 9.53E-09     |
| Cell adhesion molecules                        | 44              | 1.05E-06     |
| Lysosome                                       | 34              | 2.22E-05     |
| Intestinal immune network for IgA production   | 20              | 3.75E-05     |
| Graft-versus-host disease                      | 20              | 1.14E-04     |
| Dilated cardiomyopathy                         | 27              | 1.16E-04     |
| Glycolysis / Gluconeogenesis                    | 22              | 1.32E-04     |
| ECM-receptor interaction                       | 24              | 3.88E-04     |
| Hypertrophic cardiomyopathy                    | 24              | 4.69E-04     |
| Leukocyte transendothelial migration           | 30              | 7.67E-04     |
| Chemokine signaling pathway                    | 41              | 8.24E-04     |
| Jak-STAT signaling pathway                     | 35              | 0.0014       |
| Arrhythmogenic right ventricular cardiomyopathy| 21              | 0.0015       |
| Glutathione metabolism                         | 16              | 0.0025       |
| Asthma                                         | 12              | 0.0026       |
| Type I diabetes mellitus                       | 18              | 0.0029       |
| Allograft rejection                            | 17              | 0.0030       |
| Pentose phosphate pathway                      | 10              | 0.0048       |
| Natural killer cell mediated cytotoxicity      | 28              | 0.0050       |

\(\text{doi:10.1371/journal.pone.0130495.t001}\)

Table 2. KEGG pathways overrepresented by genes down-regulated downstream of E2A-PBX1.

| KEGG pathway term                              | Number of genes | \(P\) value  |
|------------------------------------------------|-----------------|--------------|
| Focal adhesion                                 | 47              | 1.23E-08     |
| Axon guidance                                  | 31              | 6.24E-06     |
| Pathways in cancer                             | 56              | 2.23E-05     |
| B cell receptor signaling pathway              | 21              | 5.98E-05     |
| ECM-receptor interaction                       | 21              | 1.04E-04     |
| Small cell lung cancer                         | 21              | 1.49E-04     |
| Colorectal cancer                              | 21              | 1.76E-04     |
| Hematopoietic cell lineage                     | 20              | 3.72E-04     |
| Base excision repair                           | 12              | 0.0011       |
| Primary immunodeficiency                       | 11              | 0.0018       |
| Wnt signaling pathway                          | 27              | 0.0024       |
| Vascular smooth muscle contraction             | 23              | 0.0027       |
| MAPK signaling pathway                         | 41              | 0.0033       |
| Mismatch repair                                | 8               | 0.0038       |
| Drug metabolism                                | 16              | 0.0053       |
| Adherens junction                              | 16              | 0.0061       |
| Histidine metabolism                           | 8               | 0.0083       |
| Glutathione metabolism                         | 12              | 0.0105       |
| Glycerolipid metabolism                        | 11              | 0.0138       |
| VEGF signaling pathway                         | 15              | 0.0144       |

\(\text{doi:10.1371/journal.pone.0130495.t002}\)
E2A-PBX1-expressing FLPs to commit to the B-lymphoid lineage, their retention of myeloid potential and their proliferative and leukemogenic properties.

**Ectopic expression of Hoxa9, but not Bmi1, antagonizes B-lymphoid differentiation in vitro**

Of the differentially regulated genes uncovered by expression analysis, Hoxa9 is an especially attractive candidate as a mediator of E2A-PBX1-induced hematopoietic effects in our experiments. Hoxa9 is expressed abundantly in HSCs and early progenitors and subsequently down-regulated in more mature progenitors [25]. Abundant expression of HOXA9 in clinical samples of acute myelogenous leukemia is associated with adverse clinical outcomes [26]. Enforced expression of Hoxa9 in murine hematopoietic progenitors antagonizes lymphopoiesis and, in collaboration with Meis1, induces myeloproliferative neoplasia [27–29]. Our microarray analysis indicated 40-fold higher expression of Hoxa9 in E2A-PBX1-expressing FLPs relative to vector-infected pro-B-cells (S2 Table) whereas qRT-PCR applied to independent cell preparations indicated 134-fold higher expression (Fig 7A). Accordingly, FLPs were transduced with a Hoxa9 retrovirus and grown under B-lymphopoietic conditions in order to investigate whether enforced expression of Hoxa9 could replicate the phenotype produced by E2A-PBX1. Flow cytometry carried out 14 days after transduction demonstrated that Hoxa9 blocked B-lymphoid commitment in what appeared to be a dose-dependent manner; whereas GFP-dim cells that presumably produced Hoxa9 less abundantly succeeded in achieving CD19+, CD11b− pro-B-cell status, GFP-bright cells expressing more abundant Hoxa9 instead manifested a CD19−, CD11b+ phenotype suggestive of myeloid differentiation (Fig 7B). The PcG protein Bmi1 normally silences the B-lymphopoietic transcription factor genes Ebf1 and Pax5 in early, lineage-uncommitted progenitors and has been implicated as a mediator of E2A-PBX1-driven oncogenesis [11;30]. However, the Bmi1 transcript was not over-expressed in E2A-PBX1-expressing FLPs and retrovirus-
enforced expression of Bmi1 failed to block B-lymphoid commitment (Fig 7A and 7B). These results support the notion that induction of Hoxa9, but not Bmi1, is involved in mediating E2A-PBX1-dependent antagonism of B-lymphopoiesis in our experimental model.

**E2A-PBX1 induces cell cycle arrest and apoptosis in committed B-lymphoid progenitors**

In clinical samples of t(1;19)-positive ALL, the presence of random nucleotides at the fusion point between E2A- and PBX1-derived exons and the tight clustering of breakpoints in the E2A locus suggest that the translocation may be mediated by the recombinase machinery that normally mediates immunoglobulin gene rearrangements [31]. Thus, the pre-B-cell phenotype typically observed in cases of t(1;19)-associated ALL could reflect occurrence of the leukemia-initiating translocation event in a committed B-lymphoid progenitor. In an attempt to model this leukemogenic event, FLP-derived pro-B-cells were transduced with an E2A-PBX1-expressing retroviral vector and then monitored for GFP prevalence by flow cytometry (Fig 8A). The prevalence of E2A-PBX1/GFP-expressing cells declined over time in culture, indicating that E2A-PBX1 exerts an anti-proliferative effect; this experiment was carried out twice with equivalent results (data not shown). Next, mean fluorescence intensity (MFI) for GFP was followed over time in FLP-derived pro-B-cells versus lin- FLPS after transduction with a E2A-PBX1/GFP-expressing retrovirus (Fig 8B). In lin- FLPS the MFI increased over time, consistent with the results shown in Fig 2A and suggesting that clones expressing abundant E2A-PBX1 derive a proliferative advantage. In contrast, the MFI amongst pro-B-cells declined over time, implying selection against clones expressing higher levels of E2A-PBX1. Equivalent results were obtained in multiple experiments. In order to investigate the mechanism by which E2A-PBX1 exerts its anti-proliferative effects we developed a system in which the function of E2A-PBX1 could be regulated in committed murine B-lymphoid progenitors. "Pre-B-1" cells from the bone marrow of adult mice were isolated, expanded ex vivo according to an established protocol [8], and rendered stromal cell- and IL-7-independent by stable, retrovirus-mediated expression of p210<sup>BCR-ABL</sup>. These cells were then transduced with a retrovirus conferring expression of EP<sub>Δ623ER</sub>, an estrogen-dependent derivative of E2A-PBX1 [32]; the resulting CD19<sup>+</sup> cell line was denoted 3PER12. 3PER12 cells cultured for 72 hours in the presence of estradiol (E2) appeared small and refractile, suggesting the occurrence of widespread apoptosis, whereas control cells treated with vehicle alone, or the parent cell line treated with E2, appeared unaffected (S2 Fig and data not shown). Counts of viable cells demonstrated markedly reduced proliferation over 72 hours (Fig 8C) and cell cycle analysis determined that the majority of cells treated with E2 were arrested in G1 (Fig 8D). In comparison with vehicle-treated controls, 3PER12 cells treated with E2 displayed a marked increase in apoptosis (Fig 8E). These results indicate that, whereas E2A-PBX1 is demonstrably oncogenic when introduced into uncommitted murine hematopoietic cells, when expressed in committed B-lymphoid progenitors it induces cell cycle arrest and apoptosis.

**Discussion**

The availability of an experimentally tractable murine model in which enforced expression of E2A-PBX1 gives rise to B-lymphoid neoplasia would greatly advance efforts to elucidate the molecular mechanisms involved in E2A-PBX1-driven ALL. Accordingly, much of the impetus for the current study arose from a desire to understand the observation that mice transplanted with E2A-PBX1-tranduced bone marrow succumb mostly to myeloid rather than B-lymphoid neoplasms [5;6;33]. We also considered that elucidating differential effects of E2A-PBX1 expression on hematopoietic progenitors of diverse lineages would provide insights into
Fig 8. E2A-PBX1 induces cell cycle arrest and apoptosis in committed B-lymphoid progenitors. (A) FLP-derived pro-B-cells were infected with GFP-expressing retroviral vectors and the proportion of GFP+ cells was followed over time by flow cytometry. The graph shows the proportion of GFP+ cells relative to the value determined on day 3 after each transduction. (B) FLP-derived pro-B-cells versus Lin- FLPs were infected with a retroviral vector that co-expresses GFP and E2A-PBX1 and then the mean fluorescence intensity (MFI) amongst GFP+ cells was followed over time by flow cytometry. (C) 3PER12 cells, pre-B1-derived cells that stably express EPΔ623ER, an engineered, estrogen-regulatable variant of E2A-PBX1, were induced with 10 μM estradiol (E2) versus ethanol alone (vehicle) and the accumulation of viable, Trypan blue-excluding cells over the next 72 hours was determined. (D) Flow cytometry-based cell cycle analysis of 3PER12 cells after 72 hours of induction with E2 versus vehicle. (E) Flow cytometry-based detection of apoptosis in 3PER12 cells. Cells in early apoptosis (annexin V+, propidium iodide-) or late apoptosis or death (annexin V+, propidium iodide+) are more numerous after E2 induction. Cells treated with dexamethasone (Dex) serve as a positive control.

doi:10.1371/journal.pone.0130495.g008
E2A-PBX1 function that would inform future, more directly mechanistic studies. Our findings indicate that, when expressed in uncommitted progenitors, E2A-PBX1 antagonizes aspects of both myeloid and lymphoid maturation and enforces the persistence of phenotypic features characteristic of HSCs or early progenitors. Our results also demonstrate differential E2A-PBX1-mediated effects on lymphoid relative to myeloid differentiation: whereas impairment of myeloid differentiation is merely relative such that it permits the expansion of leukemogenic myeloid progenitors in a myeloid-inductive local environment, the block to B-lymphopoiesis is near-absolute. Furthermore, in contrast to the selective advantage it confers when introduced into uncommitted progenitors, E2A-PBX1 causes cell cycle arrest and apoptosis in committed B-lymphoid progenitors. Therefore, our results demonstrate that the phenotype conferred by E2A-PBX1 is critically dependent on the maturity and lineage of the hematopoietic cells into which it is introduced.

Several recent findings allow us to speculate as to how E2A-PBX1 might perturb hematopoiesis when it is introduced into lin- progenitors. Lineage specification is governed to an important degree by the lineage-specific activity of enhancers [34]. Wild-type PBX1 has been shown to bind DNA in a manner influenced by the presence of specific chromatin marks, and the leukemogenic transcription factors PML-RARα and AML1-ETO were shown recently to bind preferentially to enhancers that are associated with accessible chromatin and local binding by p300 [35;36]. Our results suggesting that E2A-PBX1 must bind to DNA by means of the PBX1-derived homeodomain in order to abrogate the lymphoid lineage potential of uncommitted progenitors (Fig 3) are consistent with previous results indicating that the PBX1-derived homeodomain is required for impeding myeloid differentiation by E2A-PBX1 [19;37]. Therefore, it is reasonable to suggest that, upon its introduction into uncommitted progenitors, E2A-PBX1 binds regulatory elements through a mechanism that involves the PBX1 homeodomain and in a genomic distribution that is determined in part by the status of local chromatin. It may then associate with transcriptional co-regulators including CBP/p300 and perturb enhancer function, thereby impairing normal maturation and promoting the expansion of progenitors that remain responsive to myeloid-inductive environmental stimuli but blocked in a proliferative stage of development. Hematopoietic lineage specification is associated with major alterations in the accessibility of the chromatin at, in particular, lineage-specific enhancers and a progressive, overall decrease in chromatin accessibility [38]. Thus, the striking effect of the stage of hematopoietic cell differentiation that we have demonstrated on the phenotypic consequences of E2A-PBX1 expression could reflect the influence of different chromatin states in determining the genomic location and downstream transcriptional consequences of E2A-PBX1 binding.

In contrast to its proliferative and oncogenic effects in lin- FLPs (Figs 1 and 2), we demonstrate that forced expression of E2A-PBX1 in FLP-derived pro-B-cells induced cell cycle arrest and apoptosis (Fig 8). The ability of E2A-PBX1 to induce apoptosis in B-lymphoid progenitors has been reported previously, albeit not in FLP-derived cells [39;40]. The distinctive response of committed B-lymphoid cells to E2A-PBX1 could reflect a cellular response to oncogene activation. For example, the ability of p185BCR-ABL to induce murine B-lineage ALL, but not myeloid neoplasia, is enhanced dramatically by inactivation of the Arf tumor suppressor gene [41]. Arf lies within the Cdkn2a locus and its product, p19Arf, can induce p53-mediated cellular senescence or apoptosis in response to oncogene activation [42]. The differential susceptibility of FLP-derived pro-B-cells to E2A-PBX1-induced apoptosis and cell cycle arrest could reflect the distinctive status of Cdkn2a in these cells; whereas this locus is epigenetically silenced in HSCs, it is poised for induction in committed B-progenitors [41]. In support of the existence of an antagonistic relationship between E2A-PBX1 and CDKN2A in the clinical context, deletions affecting CDKN2A at chromosome band 9p21 are exceptionally prevalent amongst human ALL samples associated with t(1;19) [43]. More generally, our results suggest that additional
oncogenic alterations, such as inactivation of tumor suppressors or activation of pro-survival oncogenes, may be required for the oncogenic effects of E2A-PBX1 to be manifested in B-lymphoid cells. Other possible explanations for the failure of E2A-PBX1 to impart a selective growth advantage in our FLP-derived progenitors include possible deficiencies in the specific culture conditions that we provided relative to the requirements of E2A-PBX1-expressing B-lymphoid cells, failure to target E2A-PBX1 expression to a specific, more permissive stage of B-lymphoid ontogeny, and inherent differences between human and murine progenitors.

Sykes and Kamps used an approach similar to our own to investigate how the hematopoietic fate of bone marrow cells is affected by retrovirus-driven expression of E2A-PBX1 [44]. These authors determined that unfractionated mononuclear bone marrow cells infected with an E2A-PBX1 retrovirus and then cultivated in the presence of SCF and IL-7 developed into early T-lymphoid progenitors, whereas control cells developed into CD19-expressing pro-B-cells. Although methodological differences, including the use of bone marrow- versus FLP-derived progenitors for in vitro experiments, impede direct comparison of this study with our own, it is noteworthy that, whereas the evidence supporting T-lymphoid lineage was derived exclusively from in vitro data, our current study is the first to include transplantation experiments in which the lineage potential of E2A-PBX1-expressing lin- hematopoietic cells was determined directly in reconstituted mice. Instead of an expansion of T-lymphoid progenitors, we demonstrate profound defects in thymic seeding and thymocyte development by E2A-PBX1-transduced cells and a dramatic expansion of Gr-1+/CD11b+ myelomonocytic progenitors in the bone marrow and spleen (Fig 1). These findings are corroborated in our in vitro FLP model: the lymphoid potential of lin- FLPs expressing E2A-PBX1 is blocked prior to the CLP stage (Fig 5), these FLPs are amenable to myeloid differentiation induced by GM-CSF, and they confer myeloid leukemia upon transplanted mice (Fig 4). We infer from our findings that the myeloid phenotype of the neoplasms that generally develop in mice transplanted with E2A-PBX1-expressing bone marrow is explained by a profound reduction of T- and B-lymphoid potential that is imposed early, prior to the CLP stage, coupled with retention of myeloid lineage potential. We speculate that the T-progenitor neoplasms that occasionally develop in mice transplanted with E2A-PBX1-transduced bone marrow cells may be explicable based on the relatively greater ability of E2A-PBX1-expressing progenitors to penetrate into the pool of committed T- relative to B-lymphoid progenitors (compare Fig 1A and 1C)[5].

Two of the genes that we demonstrate to be up-regulated in E2A-PBX1-expressing FLPs, Mycn and Meis1 (Fig 6B), were identified recently among genes that were down-regulated in early myeloid progenitors from Pbx1-null mice, suggesting an overlap between genes regulated by wild-type Pbx1 and E2A-PBX1 in the myeloid context [45]. Meis1 is also a dimerization partner of wild-type Pbx1 [46]. Meis1 expression has been associated with both increased self-renewal and increased SCF responsiveness [47;48]. Hoxa9 can block myeloid differentiation, immortalize myeloid progenitor cells and collaborate with Meis1 and E2A-PBX1 in the induction of murine AML [4;32;49;50]. We and other investigators have shown that Meis1 and Hoxa9 are expressed in HSCs but subsequently down-regulated during differentiation (S3 Table) [51;52]. In investigating a possible role for Hoxa9 in mediating the effects of E2A-PBX1, we observed that when lin- FLPs are infected with a Hoxa9-expressing retrovirus, only cells that express Hoxa9 especially abundantly manifest blocked B-lymphopoiesis; Hoxa9-expressing cells were enriched in cells expressing CD11b relative to cells infected with an E2A-PBX1 virus (compare Figs 7C and 2A), suggesting that Hoxa9 is less effective than E2A-PBX1 in blocking myeloid differentiation. These observations suggest that factors in addition to Hoxa9 contribute to the differentiation block imposed by E2A-PBX1. Especially pertinent to this possibility are the findings of Wang and colleagues, who showed that lin- bone marrow-derived progenitors subjected to retrovirus-enforced co-expression of Hoxa9 and Meis1 were more impaired with
respect to B-lymphopoiesis and more potent in initiating acute myeloid leukemia than were cells transduced with *Hoxa9* alone, suggesting that Hoxa9 and Meis1 may cooperate to mediate the hematopoietic effects of E2A-PBX1 that we observed in our experiments [53].

In conclusion, our results suggest that the failure of mouse bone marrow transplantation experiments to model E2A-PBX1-induced B-lymphoid neoplasia is attributable to the ability of E2A-PBX1 to block B-lymphoid commitment prior to the CLP stage while permitting retention of myeloid potential.

**Supporting Information**

S1 Fig. Growth curves are shown from lin- fetal liver cells infected with a retroviral vector expressing E2A-PBX1b (EP1b, dashed lines) or a control, empty vector (MIEV, solid lines). Results are shown for experiments lasting 14 (red lines) or 15 (blue lines) days after retroviral transduction.

(TIF)

S2 Fig. Effects of the functional induction of E2A-PBX1 on the morphology of B-lymphoid progenitors. B-lymphoid 3PER12 cells stably expressing E3Δ623ER and cultured for 72 hours in the presence of estradiol (E2) appeared small and refractile compared to control cells treated with ethanol alone (vehicle), suggesting the occurrence of widespread apoptosis.

(TIF)

S1 Table. Antibodies used for flow cytometry.

(DOCX)

S2 Table. Genes expressed differentially at least four-fold in E2A-PBX1-expressing fetal liver progenitors relative to control pro-B-cells.

(XLSX)

S3 Table. Expression patterns of genes expressed differentially downstream of E2A-PBX1 in primary lin- and myeloid cells.

(XLSX)

S4 Table. Probe ID numbers of genes in KEGG pathways overrepresented by genes up-regulated downstream of E2A-PBX1.

(XLSX)

S5 Table. Probe ID numbers of genes in KEGG pathways overrepresented by genes down-regulated downstream of E2A-PBX1.

(XLSX)

**Acknowledgments**

We wish to thank Erin Burnett for assistance with mouse husbandry, Dr. Barbara Kee for helpful advice on experimental procedures, Dr. Christopher Paige for providing the J558-IL-7 cells, Dr. Juan Carlos Zúñiga-Pflücker for providing OP9 cells, and Dr. Mark Kamps for providing the pGD-E2A-PBX1-N51S vector.

**Author Contributions**

Conceived and designed the experiments: MWW SPS DPL. Performed the experiments: MWW PT RKS. Analyzed the data: MWW KN PT SPS RKS DPL KT. Contributed reagents/materials/analysis tools: RKS KT DPL. Wrote the paper: MWW KN KT SPS RKS DPL.
References

1. Carroll AJ, Crist WM, Parmley RT, Roper M, Cooper MD, Finley WH. Pre-B cell leukemia associated with chromosome translocation 1:19. Blood 1984; 63:721. PMID:6607758

2. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. Journal of Clinical Oncology 1994; 12(12):2601–6. PMID:7989935

3. Dedera DA, Waller EK, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 1993; 74(5):835–43. PMID:8104101

4. Bijl J, Sauvageau M, Thompson A, Sauvageau G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev 2005 Jan 15; 19(2):224–33. PMID:15655112

5. Bayly R, Murase T, Hyndman BD, Savage R, Nurmohamed S, Munro K, et al. Critical role for a single leucine residue in leukemia induction by E2A-PBX1. Mol Cell Biol 2006 Sep; 26(17):6442–52. PMID:16914730

6. Kamps MP, Baltimore D. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol 1993; 13(1):351–7. PMID:8093327

7. Cho SK, Webber TD, Carlyle JR, Nakano T, Lewis SM, Zuniga-Pflucker JC. Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. Proc Natl Acad Sci U S A 1999 Aug 17; 96(17):9797–802. PMID:10449774

8. Rolink A. B-Cell Development and Pre-B-1 Cell Plasticity In Vitro. In: Gu H, Rajewsky K, editors. B Cell Protocols. Totowa, New Jersey: Humana Press; 2004. p. 271–81.

9. Bayly R, Chuen L, Currie RA, Hyndman RD, Casselman R, Blobel GA, et al. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. J Biol Chem 2004 Dec 31; 279(53):55362–71. PMID:15507449

10. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006; 1(1):179–85. PMID:17406230

11. Oguro H, Yuan J, Ichikawa H, Ikawa T, Yamazaki S, Kawamoto H, et al. Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell 2010 Mar 5; 6(3):279–86. doi: 10.1016/j.stem.2010.01.005 PMID:20207230

12. Tukey JW. Exploratory data analysis. Biometrical J [4: ]. 413–414. 1977.

13. Lopez-Romero P. Agi4x44PreProcess: PreProcessing of Agilent 4x44 array data. Bioconductor. 2012. Available: http://www.bioconductor.org/packages/2.10/bioc/html/Agi4x44PreProcess.html

14. Vieira P, Cunhato A. Differentiation of B lymphocytes from hematopoietic stem cells. Methods Mol Biol 2004; 271:67–76. PMID:15146113

15. Hoaglin DC, Iglewicz B. Fine-tuning some resistant rules for outlier labeling. J Am Stat Assoc 82[400], 1147–1149. 1987. PMID:12155376

16. Bhandoola A, von BH, Petrie HT, Zuniga-Pflucker JC. Commitment and developmental potential of extrathymic and intrathymic T cell precursors: plenty to choose from. Immunity 2007 Jun; 26(6):678–89. PMID:17582341

17. Bhandoola A, van BH, Petrie HT, Zuniga-Pflucker JC. Commitment and developmental potential of extrathymic and intrathymic T cell precursors: plenty to choose from. Immunity 2007 Jun; 26(6):678–89. PMID:17582341

18. Vieira P, Cunha A. Differentiation of B lymphocytes from hematopoietic stem cells. Methods Mol Biol 2004; 271:67–76. PMID:15146113

19. Monica K, LeBrun DP, Dedera DA, Brown RB, Cleary ML. Transformation properties of the E2a-Pbx1 chimeric oncprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable. Mol Cell Biol 1994; 14(12):8304–14. PMID:7969166

20. Bhalla S, Spaulding C, Brumbaugh RL, Zagort DE, Massari ME, Murre C, et al. Differential roles for the E2A activation domains in B lymphocytes and macrophages. J Immunol 2008 Feb 1; 180(3):1694–703. PMID:18209066

21. Knoepfler PS, Calvo KR, Chen H, Antonarakis SE, Kamps MP, Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncprotein E2a-Pbx1. Proc Natl Acad Sci USA 1997; 94(26):14553–8. PMID:9405651

22. Denis CM, Langeland DN, Kirlin AC, Chitayat S, Munro K, Spencer HL, et al. Functional redundancy between the transcriptional activation domains of E2A is mediated by binding to the KIX domain of CBP/p300. Nucleic Acids Res 2014; 42(11):7370–82. doi: 10.1093/nar/gku206 PMID:24682819
23. de Pooter RF, Kee BL. E proteins and the regulation of early lymphocyte development. Immunol Rev
2010 Nov; 238(1):93–109. doi: 10.1111/j.1600-065X.2010.00957.x PMID: 20969587

24. Jiao X, Sherman BT, Huang dW, Stephens R, Baseler MW, Lane HC, et al. DAVID-WS: a stateful web
service to facilitate gene/protein list analysis. Bioinformatics 2012 Jul 1; 28(13):1805–6. doi: 10.1093/
bioinformatics/bts251 PMID: 22543366

25. Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression of Hox, Meis1, and
Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 2002 Jan; 30
(1):49–57. PMID: 11823037

26. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification
of cancer: class discovery and class prediction by gene expression monitoring. Science 1999 Oct 15;
286(5439):531–7. PMID: 10521349

27. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijj, Lawrence HJ, et al. Overexpression of the mye-
loid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002
Jan 1; 99(1):121–9. PMID: 11756111

28. Kroon E, Kosj, L, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary
bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17
(13):3714–25. PMID: 9649441

29. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation
by HOXA cluster genes. Blood 2010 Apr 8; 115(14):2910–8. doi: 10.1182/blood-2009-04-216606
PMID: 20130239

30. Smith KS, Chanda SK, Lingbeek M, Ross DT, Botstein D, van LM, et al. Bmi-1 regulation of INK4A-
ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol
Cell 2003 Aug; 12(2):393–400. PMID: 14536079

31. Wiemels JL, Leonard BC, Wang Y, Segal MR, Hunger SP, Smith MT, et al. Site-specific translocation
and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leuke-
mia. Proc Natl Acad Sci U S A 2002 Nov 12; 99(23):15101–6. PMID: 12415113

32. Sykes DB, Kamps MP. Estrogen-dependent E2a/Pbx1 myeloid cell lines exhibit conditional differentia-
tion that can be arrested by other leukemic oncoproteins. Blood 2001 Oct 15; 98(6):2308–18. PMID:
11588024

33. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001 Apr; 38
(2):124–38. PMID: 11309694

34. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, et al. Histone modifications at
human enhancers reflect global cell-type-specific gene expression. Nature 2009 May 7; 459
(7243):108–12. doi: 10.1038/nature07829 PMID: 19295514

35. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERalpha signal-
ing underlying progression in breast cancer. PLoS Genet 2011 Nov; 7(11):e1002368. doi:10.1371/
journal.pgen.1002368 PMID: 22125492

36. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, et al. Chromatin accessibility,
p300, and histone acetylation define PML-RAalpha and AML1-ETO binding sites in acute myeloid leukemias.
Blood 2012 Oct 1; 120(15):3058–68. doi: 10.1182/blood-2011-10-386086 PMID: 22923494

37. Kamps MP, Wright DD, Lu Q. DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differenti-
ation but dispensable for fibroblast transformation. Oncogene 1996; 12(1):19–30. PMID: 8552391

38. Zhu J, Adli M, Zou JY, Verstappen G, Coyne M, Zhang X, et al. Genome-wide chromatin state transi-
tions associated with developmental and environmental cues. Cell 2013 Jan 31; 152(3):642–54. doi:
10.1016/j.cell.2012.12.033 PMID: 23333102

39. Smith KS, Jacobs Y, Chang CP, Cleary ML. Chimeric oncoprotein E2a-Pbx1 induces apoptosis of
hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2. Oncogene 1997; 14
(24):2917–26. PMID: 9205098

40. Rutherford MN, Bayly GR, Matthews BP, Okuda T, Dinjens WM, Kondoh H, et al. The leukemogenic
transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in
Ba/F3 cells. Leukemia 2001 Mar; 15(3):362–70. PMID: 11237058

41. Williams RT, Sherr CJ. The INK4a-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leu-
kemias. Cold Spring Harb Symp Quant Biol 2008; 73:461–7. doi: 10.1101/sqb.2008.73.039 PMID:
19028987

42. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.
Nat Rev Mol Cell Biol 2006 Sep; 7(9):667–77. PMID: 16921403

43. Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, et al. A comprehensive analysis of
the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number
neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 2009 Jan 1; 113(1):100–7. doi: 10.1182/blood-2008-07-166801 PMID: 18838613

44. Sykes DB, Kamps MP. E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-T cells that cause acute T-lymphoid or myeloid leukemias in mice. Mol Cell Biol 2004 Feb; 24 (3):1256–69. PMID: 14729970

45. Ficara F, Crisafulli L, Lin C, Iwasaki M, Smith KS, Zammataro L, et al. Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors. J Cell Sci 2013 Jul 15; 126(Pt 14):3181–91. doi: 10.1242/jcs.125435 PMID: 23660001

46. Chang CP, Jacobs Y, Nakamura T, Jenkins NA, Copeland NG, Cleary ML. Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins. Mol Cell Biol 1997; 17 (10):5679–87. PMID: 9315626

47. Dias S, Mansson R, Gurbuxani S, Sigvardsson M, Kee BL. E2A proteins promote development of lymphoid-primed multipotent progenitors. Immunity 2008 Aug 15; 29(2):217–27. doi: 10.1016/j.immuni.2008.05.015 PMID: 18674933

48. Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci U S A 2001 Nov 6; 98(23):13120–5. PMID: 11687616

49. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol Cell Biol 2000 May; 20(9):3274–85. PMID: 10757811

50. Nakamura T, Largaespada DA, Shaughnessy JD Jr., Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukemias. Nature Genetics 1996; 12(2):149–53. PMID: 8563752

51. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 1999 May; 13(3):687–98. PMID: 10374871

52. Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Komuves L, et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999 Dec; 13 (12):1993–9. PMID: 10602420

53. Wang GG, Pasillas MP, Kamps MP. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood 2005 Jul 1; 106(1):254–64. PMID: 15755900